Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients

Finckh, Axel; Dudler, Jean; Wermelinger, Felix; Ciurea, Adrian; Kyburz, Diego; Gabay, Cem; Bas, Sylvette; physicians of SCQM, (2010). Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint bone spine, 77(4), pp. 313-8. Paris: Elsevier Masson SAS 10.1016/j.jbspin.2010.02.021

Full text not available from this repository. (Request a copy)

Infliximab (IFX) can be immunogenic for humans and lead to the formation of antibodies against IFX (anti-IFX Ab), which could induce acquired IFX resistance.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Wermelinger, Felix

ISSN:

1297-319X

Publisher:

Elsevier Masson SAS

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:11

Last Modified:

04 May 2014 23:05

Publisher DOI:

10.1016/j.jbspin.2010.02.021

PubMed ID:

20471890

Web of Science ID:

000281783700006

URI:

https://boris.unibe.ch/id/eprint/1698 (FactScience: 203582)

Actions (login required)

Edit item Edit item
Provide Feedback